<!DOCTYPE html>
<html lang="en">

<head>
  <title>CHF | The Peripheral Brain</title>
  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">

  <script src='https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.2/MathJax.js?config=TeX-MML-AM_CHTML'></script>

  <link rel="stylesheet" href="/peripheral_brain/css/main.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/mobile.css" />
  <link rel="stylesheet" href="/peripheral_brain/css/buttons.css" />

  
    <link rel="stylesheet" href="/peripheral_brain/css/diseases.css">
  


  <link href="https://fonts.googleapis.com/css?family=Open+Sans" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Slab" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Mono" rel="stylesheet">
  <link href="https://fonts.googleapis.com/css?family=Roboto+Condensed" rel="stylesheet">


  <link rel="apple-touch-icon" sizes="180x180" href="/peripheral_brain/favicons/apple-touch-icon.png">
  <link rel="icon" type="image/png" sizes="32x32" href="/peripheral_brain/favicons/favicon-32x32.png">
  <link rel="icon" type="image/png" sizes="16x16" href="/peripheral_brain/favicons/favicon-16x16.png">
  <link rel="manifest" href="/peripheral_brain/favicons/site.webmanifest">
  <link rel="mask-icon" href="/peripheral_brain/favicons/safari-pinned-tab.svg" color="#465c8b">
  <link rel="shortcut icon" href="/peripheral_brain/favicons/favicon.ico">
  <meta name="apple-mobile-web-app-title" content="Peripheral Brain">
  <meta name="application-name" content="Peripheral Brain">
  <meta name="msapplication-TileColor" content="#da532c">
  <meta name="msapplication-config" content="/peripheral_brain/favicons/browserconfig.xml">
  <meta name="theme-color" content="#cdcdcd">


  

</head>


<body class="body">
<header id="myHeader" class="myHeader">
  <nav>
    <!-- <a href="/peripheral_brain/home.html"><img src="/peripheral_brain/images/logo_1000x1000.png" alt="Logo"> -->
    <a href="/peripheral_brain/home.html">Home</a>
    <a href="/peripheral_brain/disease_list.html">Diseases and Drugs</a>
    <a href="/peripheral_brain/firstFive">TF5M</a>
    <a href="/peripheral_brain/lab_values">Lab Values</a>
    <a href="/peripheral_brain/formulas">Formulas</a>
    <a href="/peripheral_brain/calculators.html">Calculators</a>
    <a href="/peripheral_brain/search.html">Search</a>
    <a href="javascript:void(0);" class="icon" onclick="openMenu()">&#9776;</a>
  </nav>

  <script>
  function openMenu() {
      var x = document.getElementById("myHeader");
      if (x.className === "myHeader") {
          x.className += " responsive";
      } else {
          x.className = "myHeader";
      }
  }
  </script>
</header>


<h1 class="title">CHF</h1>

<div class="contents twoCol">
  <div class="toc col1">
    
      <ul>
  <li><a href="#dx">Dx<sup id="fnref:yancy2013"><a href="#fn:yancy2013" class="footnote">1</a></sup></a>
    <ul>
      <li><a href="#staging--classification">Staging / Classification</a></li>
      <li><a href="#ddx-of-dilated-cardiomyopathies">DDx of Dilated Cardiomyopathies</a></li>
    </ul>
  </li>
  <li><a href="#tx-hfref-">Tx (HFrEF)<sup id="fnref:yancy2013:1"><a href="#fn:yancy2013" class="footnote">1</a></sup><sup>,</sup> <sup id="fnref:yancy2017"><a href="#fn:yancy2017" class="footnote">2</a></sup></a>
    <ul>
      <li><a href="#stage-a">Stage A</a></li>
      <li><a href="#stage-b">Stage B</a></li>
      <li><a href="#stage-c">Stage C</a></li>
      <li><a href="#dosing">Dosing</a></li>
      <li><a href="#stage-d">Stage D</a></li>
    </ul>
  </li>
  <li><a href="#acute-decompensated-hf-">Acute Decompensated HF<sup id="fnref:yancy2013:2"><a href="#fn:yancy2013" class="footnote">1</a></sup><sup>,</sup> <sup id="fnref:tintinalli"><a href="#fn:tintinalli" class="footnote">3</a></sup></a></li>
  <li><a href="#references">References</a></li>
</ul>

    
  </div>

  <div class="content col2">
    <h1 id="dx">Dx<sup id="fnref:yancy2013"><a href="#fn:yancy2013" class="footnote">1</a></sup></h1>

<ul>
  <li>HFrEF: HF w/ LVEF ≤ 40%</li>
  <li>HFpEF: HF w/ LVEF ≥ 50%
    <ul>
      <li>&gt; 40% is borderline HFpEF</li>
    </ul>
  </li>
  <li>Measure NT-proBNP or BNP if suspicious</li>
  <li>CXR and Doppler Echo on initial workup</li>
</ul>

<h2 id="staging--classification">Staging / Classification</h2>

<p class="caption">AHA Stages</p>

<table>
  <thead>
    <tr>
      <th>Stage</th>
      <th>Description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>A</td>
      <td>High risk w/o structural heart disease and w/o HF SSx</td>
    </tr>
    <tr>
      <td>B</td>
      <td>SHD w/o SSx of HF</td>
    </tr>
    <tr>
      <td>C</td>
      <td>SHD w/ current or prior HF SSx</td>
    </tr>
    <tr>
      <td>D</td>
      <td>Refractory HF SSx</td>
    </tr>
  </tbody>
</table>

<p class="caption">NYHA Classifications</p>

<table>
  <thead>
    <tr>
      <th>Classification</th>
      <th>Description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>I</td>
      <td>No limitations of physical activity d/t SSx</td>
    </tr>
    <tr>
      <td>II</td>
      <td>Normal physical activity results in SSx</td>
    </tr>
    <tr>
      <td>III</td>
      <td>Mild physical activity results in SSx</td>
    </tr>
    <tr>
      <td>IV</td>
      <td>SSx at rest</td>
    </tr>
  </tbody>
</table>

<h2 id="ddx-of-dilated-cardiomyopathies">DDx of Dilated Cardiomyopathies</h2>

<ul>
  <li>Genetic / Familial</li>
  <li>Obesity</li>
  <li>DM</li>
  <li>Hyperthyroidism</li>
  <li>Acromegaly</li>
  <li>EtOH</li>
  <li>Cocaine</li>
  <li>HER-2 and/or anthracyclines</li>
  <li>Various other toxins</li>
  <li>Chronic Tachycardia</li>
  <li>Myocarditis
    <ul>
      <li>SLE</li>
      <li>HIV</li>
      <li>Other infections</li>
      <li>Chagas disease</li>
      <li>Hypersensitivity myocarditis</li>
      <li>Scleroderma and other rheumatologist conditions</li>
    </ul>
  </li>
  <li>Peripartum cardiomyopathy</li>
  <li>Hemochromatosis and iron overload</li>
  <li>Amyloidosis</li>
</ul>

<h1 id="tx-hfref-">Tx (HFrEF)<sup id="fnref:yancy2013:1"><a href="#fn:yancy2013" class="footnote">1</a></sup><sup>,</sup> <sup id="fnref:yancy2017"><a href="#fn:yancy2017" class="footnote">2</a></sup></h1>

<h2 id="stage-a">Stage A</h2>

<ul>
  <li>Modify risk factors as appropriate, with emphasis on wt loss, smoking cessation, BP control, HLD control, and DM control</li>
</ul>

<h2 id="stage-b">Stage B</h2>

<p>All pts should receive…</p>

<ul>
  <li>ACEI (ARB if CI)</li>
  <li>β-blocker
    <ul>
      <li>Metoprolol tartrate</li>
      <li>Bisoprolol</li>
      <li>Carvedilol</li>
    </ul>
  </li>
  <li>Statins (if Hx of ACS or CAD)</li>
  <li>Other means of BP control PRN
    <ul>
      <li>Consider spironolactone if HTN is refractory to above agents</li>
    </ul>
  </li>
  <li>Consider prophylactic ICD</li>
</ul>

<h2 id="stage-c">Stage C</h2>

<p>All pts should receive…</p>

<ul>
  <li>ACEI or ARB or ARNI
    <ul>
      <li>Tolerating ACEI or ARB and able to afford =&gt; transition to ARNI</li>
      <li><strong>Do not give ARNI w/i 36hr of ACEI or ARB</strong></li>
      <li><strong>Do not give ARNIs to pts w/ Hx of angioedema</strong></li>
      <li>Monitor and titrate slowly Q1-2wks</li>
    </ul>
  </li>
  <li>β-blocker
    <ul>
      <li>Metoprolol tartrate</li>
      <li>Bisoprolol</li>
      <li>Carvedilol</li>
      <li>Consider ivabridine if on maximum BB dose, LVEF ≤ 35%, and RHR ≥ 70</li>
      <li>Start low and titrate up when SSx of current dose abide</li>
    </ul>
  </li>
  <li>Spironolactone
    <ul>
      <li>CrCl &gt; 30 and K &lt; 5</li>
      <li>If LVEF ≤ 35% OR LVEF ≤ 40% w/ HF or DM after MI</li>
    </ul>
  </li>
  <li>Consider Hydralazine-Nitrate combos in black pts</li>
  <li>PRN Diurectics for fluid status control
    <ul>
      <li>Preferably Loops, with thiazides added for diuretic resistance PRN</li>
    </ul>
  </li>
  <li>Additional BP Meds PRN for goal of &lt; 130/80</li>
  <li>Consider Digoxin to decrease hospitalizations
    <ul>
      <li>0.125-0.25mg QD NTE 0.5-0.75mg QD</li>
      <li>Goal Plasma Range of 0.5-0.9 ng/mL</li>
    </ul>
  </li>
  <li><strong>Avoid CCBs except amlodipine</strong></li>
</ul>

<h2 id="dosing">Dosing</h2>

<p class="caption">HF Drug Dosing</p>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Initial Dose</th>
      <th>Max Dose</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td colspan="3">ACEIs</td>
    </tr>
    <tr>
      <td>Captopril</td>
      <td>6.25mg TID</td>
      <td>50mg TID</td>
    </tr>
    <tr>
      <td>Enalapril</td>
      <td>2.5mg BID</td>
      <td>10-20mg BID</td>
    </tr>
    <tr>
      <td>Lisinopril</td>
      <td>2.5-5mg QD</td>
      <td>20-40mg QD</td>
    </tr>
    <tr>
      <td colspan="3">ARBs</td>
    </tr>
    <tr>
      <td>Candesartan</td>
      <td>4-8mg QD</td>
      <td>32mg QD</td>
    </tr>
    <tr>
      <td>Losartan</td>
      <td>25-50mg QD</td>
      <td>50-150mg QD</td>
    </tr>
    <tr>
      <td>Valsartan</td>
      <td>20-40mg BID</td>
      <td>160mg BID</td>
    </tr>
    <tr>
      <td colspan="3">ARNI</td>
    </tr>
    <tr>
      <td>Sacubitril/Valsartan</td>
      <td>49mg/51mg BID<br />(or 24mg/26mg BID)</td>
      <td>97mg/103mg BID</td>
    </tr>
    <tr>
      <td colspan="3">I<sub>f</sub> Channel Inhibitor</td>
    </tr>
    <tr>
      <td>Ivabradine</td>
      <td>5mg BID</td>
      <td>7.5mg BID</td>
    </tr>
    <tr>
      <td colspan="3">Aldosterone Antagonists</td>
    </tr>
    <tr>
      <td>Spironolactone</td>
      <td>12.5-25mg QD</td>
      <td>25mg QD or BID</td>
    </tr>
    <tr>
      <td>Eplerenone</td>
      <td>25mg QD</td>
      <td>50mg QD</td>
    </tr>
    <tr>
      <td colspan="3">β-Blockers</td>
    </tr>
    <tr>
      <td>Bisoprolol</td>
      <td>1.25mg QD</td>
      <td>10mg QD</td>
    </tr>
    <tr>
      <td>Carvedilol</td>
      <td>3.125mg BID</td>
      <td>50mg BID</td>
    </tr>
    <tr>
      <td>Carvedilol CR</td>
      <td>10mg QD</td>
      <td>80mg QD</td>
    </tr>
    <tr>
      <td>Metoprolol Succinate</td>
      <td>12.5-25mg QD</td>
      <td>200mg QD</td>
    </tr>
    <tr>
      <td colspan="3">ISDN-Hydralazine</td>
    </tr>
    <tr>
      <td>Combo Pill</td>
      <td>20mg/37.5mg TID</td>
      <td>40mg/75mg TID</td>
    </tr>
    <tr>
      <td>Individual Pills</td>
      <td>20-30mg/25-50mg TID or QD</td>
      <td>40mg TID / 100mg TID</td>
    </tr>
  </tbody>
</table>
<p class="caption">HF Diuretic Dosing</p>

<table>
  <thead>
    <tr>
      <th>Drug</th>
      <th>Initial Dose</th>
      <th>Max TDD</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td colspan="3">Loops</td>
    </tr>
    <tr>
      <td>Bumetanide</td>
      <td>0.5-1mg QD-BID</td>
      <td>10mg</td>
    </tr>
    <tr>
      <td>Furosemide</td>
      <td>20-40mg QD-BID</td>
      <td>600mg</td>
    </tr>
    <tr>
      <td>Torsemide</td>
      <td>10-20mg QD</td>
      <td>200mg</td>
    </tr>
    <tr>
      <td colspan="3">Thiazides</td>
    </tr>
    <tr>
      <td>Chlorthiazide</td>
      <td>250-500mg QD-BID</td>
      <td>1000mg</td>
    </tr>
    <tr>
      <td>Chlorthalidone</td>
      <td>12.5-25mg QD</td>
      <td>100mg</td>
    </tr>
    <tr>
      <td>HCTZ</td>
      <td>25mg QD or BID</td>
      <td>200mg</td>
    </tr>
    <tr>
      <td>Indapamide</td>
      <td>2.5mg QD</td>
      <td>5mg</td>
    </tr>
    <tr>
      <td>Metolazone</td>
      <td>2.5mg QD</td>
      <td>20mg</td>
    </tr>
    <tr>
      <td colspan="3">K-Sparing</td>
    </tr>
    <tr>
      <td>Amiloride</td>
      <td>5mg QD</td>
      <td>20mg</td>
    </tr>
    <tr>
      <td>Spironolactone</td>
      <td>12.5-25 QD</td>
      <td>50mg</td>
    </tr>
    <tr>
      <td>Triamterene</td>
      <td>50-75mg BID</td>
      <td>200mg</td>
    </tr>
  </tbody>
</table>
<h2 id="stage-d">Stage D</h2>

<ul>
  <li>Fluid restrict to 1.5-2 L QD</li>
  <li>Consider milrinone or dobutamine for inotropy</li>
  <li>Consider LVAD</li>
  <li>Consider transplant</li>
</ul>

<h1 id="acute-decompensated-hf-">Acute Decompensated HF<sup id="fnref:yancy2013:2"><a href="#fn:yancy2013" class="footnote">1</a></sup><sup>,</sup> <sup id="fnref:tintinalli"><a href="#fn:tintinalli" class="footnote">3</a></sup></h1>

<ul>
  <li>Continue home HF meds unless CI or hemodynamically unstable / failing renal Fx</li>
  <li>IV diuretics for fluid-overloaded pts
    <ul>
      <li>Furosemide 40mg, Bumetanide 1-3mg, or Torsemide 10-20mg for naive pts</li>
      <li>Should give higher doses than home</li>
    </ul>
  </li>
  <li>Give vasodilators if pt has adequate hemodynamics and significant dyspnea
    <ul>
      <li>NTG 0.5-0.7 mcg/kg/min IV titrated NTE 200 mcg/min</li>
      <li>Nitroprusside 0.3 mcg/kg/min titrated q5-10min</li>
      <li>Nesiritide 2mcg/kg then 0.01 mcg/kg/min<sup id="fnref:lexi"><a href="#fn:lexi" class="footnote">4</a></sup></li>
    </ul>
  </li>
  <li>Pressors / Inotropes if not perfusing
    <ul>
      <li>Milrinone 50 mcg/kg over 10min then 0.5 mcg/kg/min</li>
      <li>Dobutamine 2-20 mcg/kg/min</li>
    </ul>
  </li>
  <li>Consider LVAD or ECMO if absolutely necessary</li>
</ul>

<h1 id="references">References</h1>

<!-- Cardiology -->

<!-- ACS -->

<!-- HTN -->

<!-- VTE -->

<!-- CHF -->

<!-- HLD -->

<!-- Critical Care -->

<!-- Hypotension Management -->

<!-- Stress Ulcer Prophylaxis -->

<!-- ID -->

<!-- Vancomycin Dosing -->

<!-- Aminoglycoside Dosing -->

<!-- Pulmononolgy -->

<!-- Textbooks -->

<!-- Pharmacology -->

<!-- Emergency Medicine -->

<!-- Websites -->

<!-- Drug Resources -->

<div class="footnotes">
  <ol>
    <li id="fn:yancy2013">
      <p>Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. <em>Circulation</em>. 2013;128(16). doi:<a href="https://doi.org/10.1161/CIR.0b013e31829e8776">10.1161/CIR.0b013e31829e8776</a> <a href="#fnref:yancy2013" class="reversefootnote">&#8617;</a> <a href="#fnref:yancy2013:1" class="reversefootnote">&#8617;<sup>2</sup></a> <a href="#fnref:yancy2013:2" class="reversefootnote">&#8617;<sup>3</sup></a></p>
    </li>
    <li id="fn:yancy2017">
      <p>Yancy CW, Jessup M, Bozkurt B, et al. 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. <em>Journal of the American College of Cardiology</em>. 2017;70(6):776-803. doi:[10.1016/j.jacc.2017.04.025 <a href="#fnref:yancy2017" class="reversefootnote">&#8617;</a></p>
    </li>
    <li id="fn:tintinalli">
      <p>Tintinalli JE, Stapczynski JS, Ma OJ, Cline D, Meckler GD, Yealy DM, eds. <em>Tintinalli’s Emergency Medicine: A Comprehensive Study Guide</em>. Eight edition. New York: McGraw-Hill Education; 2016. <a href="#fnref:tintinalli" class="reversefootnote">&#8617;</a></p>
    </li>
    <li id="fn:lexi">
      <p>Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods, IL. Available at: <a href="http://online.lexi.com">http://online.lexi.com</a>. <a href="#fnref:lexi" class="reversefootnote">&#8617;</a></p>
    </li>
  </ol>
</div>

  </div>

</div>

<div class="credits">
  <p>Author: Corbin Cox <br>
  Created: 2018-12-17 <br>
  Last Updated: 2018-12-17</p>
</div>

<footer class="footer menus">
  <nav>
    <div class="footerLinks">
      <a href="/peripheral_brain/home.html">Home</a>
      <a href="/peripheral_brain/index.html">Disclaimer</a>
      <a href="/peripheral_brain/disease_list_old.html">Archived Diseases</a>
    </div>
  </nav>
</footer>


</body>
</html>
